Compare CRNX & SIG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRNX | SIG |
|---|---|---|
| Founded | 2008 | 1950 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.1B |
| IPO Year | 2018 | 1997 |
| Metric | CRNX | SIG |
|---|---|---|
| Price | $36.66 | $83.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 7 |
| Target Price | $76.75 | ★ $111.14 |
| AVG Volume (30 Days) | ★ 1.3M | 674.9K |
| Earning Date | 05-07-2026 | 06-02-2026 |
| Dividend Yield | N/A | ★ 1.65% |
| EPS Growth | N/A | ★ 974.07 |
| EPS | N/A | ★ 7.08 |
| Revenue | $1,039,000.00 | ★ $6,247,100,000.00 |
| Revenue This Year | $720.10 | $1.39 |
| Revenue Next Year | $184.67 | $1.71 |
| P/E Ratio | ★ N/A | $11.48 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.83 | $65.20 |
| 52 Week High | $57.99 | $110.20 |
| Indicator | CRNX | SIG |
|---|---|---|
| Relative Strength Index (RSI) | 45.46 | 51.02 |
| Support Level | $33.19 | $80.87 |
| Resistance Level | $37.23 | $95.53 |
| Average True Range (ATR) | 2.17 | 3.60 |
| MACD | -0.18 | 0.38 |
| Stochastic Oscillator | 28.47 | 71.72 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Signet Jewelers Ltd is a retailer of diamond jewelry. Its merchandise mix includes bridal, fashion, watches, and others. The bridal category includes engagement, wedding, and anniversary purchases. Its segments are the North America segment, the International segment, and the Other segment. The North America segment contributes to the majority of the revenue. The North America segment generates revenue from Mall and Outlet. Geographically, it operates in the USA, Canada, the UK, and Ireland, with the maximum revenue from the USA.